COO — Sheri Lewis: The Chief Operations, Quality and Technology Officer is resigning to pursue other opportunities, representing a loss of a senior executive.

Results of Operations and Financial Condition. On August 6, 2026, SkinHealth Systems Inc. (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Other Events. Securities Class Action On June 17, 2026, SkinHealth Systems Inc., f/k/a The Beauty Health Company (the “Company”), entered into a Stipulation and Agreement of Settlement to settle the securities class action pending in the United States District Court for the Central District of California, captioned Alghazwi v. The Beauty Health Company, et al. , Case No. 2:23-cv-09733-SPG-MAA (the “Securities Class Action” and the proposed settlement, the “Proposed Securities Settlement”). Th…

Chief Revenue Officer — Ronald Menezes: The Chief Revenue Officer was terminated without cause, representing the loss of a senior executive, though the severance terms suggest an orderly separation rather than a scandal.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On May 8, 2026, SkinHealth Systems Inc., a Delaware corporation (the “Company”), received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its Class A Common Stock, par value $0.0001 per share (the “Common Stock”), was not in compliance with Nasdaq Listing Rule 5550(a)(2) for conti…

Results of Operations and Financial Condition. On May 7, 2026, SkinHealth Systems Inc. (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Chief Revenue Officer — Ronald Menezes: The Chief Revenue Officer was terminated without cause, representing a sudden loss of a senior executive without an immediate successor.

Director — Kenneth Tripp: The filing discloses the appointment of three new directors to fill vacancies and expand the board, which is a routine governance action rather than an executive departure.

Results of Operations and Financial Condition. On March 12, 2026, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange…

Results of Operations and Financial Condition. On November 6, 2025, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act o…

Director — Dr. Philippe Schaison: The filing discloses the appointment of a new independent director to the Board, which is a routine governance event and not a departure of a senior executive.

CEO — Beck: The CEO was terminated without cause, representing a sudden loss of the top executive.

CEO — Pedro Malha: The company replaced its sitting CEO, Marla Beck, with an external candidate, Pedro Malha, representing a significant change in top leadership.

Entry into a Material Definitive Agreement. On September 4, 2025, The Beauty Health Company (the “Company”), certain domestic subsidiaries of the Company (the “Existing Guarantors”) and certain foreign subsidiaries of the Company (the “New Guarantors”) entered into Supplemental Indenture No.1 (the “Supplemental Indenture”) with U.S. Bank Trust Company, National Association, as trustee (the “Trustee”) and collateral agent (the “Collateral Agent”). The Supplemental Indenture modified that certa…

Results of Operations and Financial Condition. On August 7, 2025, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934,…

of this Current Report to the extent required. No Offer or Solicitation None of this Current Report nor the exhibits attached hereto constitutes an offer to sell, or a solicitation of an offer to buy, the Notes and related guarantees or any other securities, nor shall there be any sale of the Notes and related guarantees or any other securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws o…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On May 27, 2025, The Beauty Health Company (the “Company”) issued $250,000,000 principal amount of its 7.95% Convertible Senior Secured Notes due 2028 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of May 27, 2025, between the Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”) and collateral agent (the “ Collateral Agent…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On May 21, 2025, The Beauty Health Company (the “ Company ”) entered into privately negotiated exchange agreements (the “ Exchange Agreements ”) with certain holders (the “ Exchanging Holders ”) of the Company’s outstanding 1.25% convertible senior notes due 2026 (the “ Existing Notes ”). The Existing Notes were issued pursuant to, and are governed by, an indenture (the “ Existing Notes Indenture ”), dated as of September 14, 2021, between the Compa…

Results of Operations and Financial Condition. On May 8, 2025, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Results of Operations and Financial Condition. On March 12, 2025, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange…

Chief Revenue Officer — Ronald Menezes: The filing discloses that an existing executive's role expanded to include policy-making functions, thereby designating him as a Section 16 officer, rather than a departure or new hire.

Director — Stephen J. Fanning: The filing discloses the appointment of a new independent director to the board, which is a routine governance action and not a departure of a senior executive.

Results of Operations and Financial Condition. On November 12, 2024, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934…